Recent research have converged on the convergence of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine neurotransmission. While GCGR activators are increasingly employed for treating type 2 T2DM, their potential consequences on reinforcement circuits, specifically governed by dopaminergic pathways, are receiving considerable inte… Read More